Coamplification of HIV-1 proviral DNA and viral rna in assays used for quantification of HIV-1 RNA

Journal of Clinical Microbiology

Volumn 48, Issue 6, 2010, Pages 2186-2190

  Wan, H ^a   Seth, A ^a   Rainen, L ^b   Fernandes, H ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BD Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; EDETIC ACID; GENOMIC DNA; POL PROTEIN; VIRUS DNA; VIRUS RNA;

ALU SEQUENCE; ARTICLE; COBAS AMPLICOR MONITOR ULTRASENSITIVE TEST; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITOMETRY; DNA DETERMINATION; DNA EXTRACTION; GENE; GENE AMPLIFICATION; HEAT TREATMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS DETECTION; VIRUS EXAMINATION; VIRUS LOAD;

DEOXYRIBONUCLEASES; DIAGNOSTIC ERRORS; DNA, VIRAL; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; PROVIRUSES; RNA, VIRAL; SPECIMEN HANDLING; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77952945785     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02034-09     Document Type: Article

References (14)

1. Alvarez-Arnao, D., A. Li, B. Canedo, and C. Baleeiro. 2005. HIV RNA measurement using EDTA or PPT tubes results in different degrees of undetectability: impact on clinical practice, abstr. MoPe15.2C06. Abstr. 3rd Int. AIDS Soc. Conf. HIV Pathog. Treatment. Rio de Janeiro, Brazil, 24 to 27 July 2005. International AIDS Society, Geneva, Switzerland. http://www.aegis. com/conferences/iashivpt/2005/MoPe15-2C06.html.
2. Elbeik, T., P. Nassos, P. Kipnis, B. Haller, and V. L. Ng. 2005. Evaluation of the VACUTAINER PPT plasma preparation tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA. J. Clin. Microbiol. 43:3769-3771.
3. García-Bujalancea, S., C. Ladrón de Guevaraa, J. González-Garcíab, J. R. Arribasb, F. Zamorab, and A. Gutiérreza. 2007. Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1. J. Microbiol. Methods 69:384-386.
4. Griffith, B. P., and D. R. Mayo. 2006. Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in plasma preparation tubes. J. Clin. Virol. 35:197-200.
5. Kran, A.-M. B., T. O. Jonassen, M. Sannes, K. Jakobsen, A. Lind, A. Maeland, and M. Holberg-Petersen. 2009. Overestimation of human immuno-deficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes. J. Clin. Microbiol. 47:2170-2174.
6. Lee, P. K., T. L. Kieffer, R. F. Siliciano, and R. E. Nettles. 2006. HIV-1 viral load blips are of limited clinical significance. J. Antimicrob. Chemother. 57:803-805.
7. Lima, V., R. Harrigan, and J. S. G. Montaner. 2009. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J. Acquir. Immune Defic. Syndr. 51:3-6.
8. Nettles, R. E., and T. L. Kieffer. 2006. Update on HIV-1 viral load blips. Curr. Opin. HIV AIDS 1:157-161.
9. Rainen, L., H. Salimnia, M. Fairfax, H. Fernandes, and M. Brown. 2005. Sample handling parameters affecting performance of BD Vacutainer PPT and Plus K2 EDTA tubes with the Roche Amplicor and Cobas Amplicor HIV-1 Monitor test, version 1.5 ultrasensitive and standard specimen processing procedures. BD white paper. BD Diagnostics, Franklin Lakes, NJ.
10. Rebeiro, P. F., A. Kheshti, S. S. Bebawy, S. E. Stinnette, H. Erdem, Y. W. Tang, T. R. Sterling, S. P. Raffanti, and R. T. D'Aquila. 2008. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin. Infect. Dis. 47:1354-1357.
11. Salimnia, H., E. C. Moore, L. R. Crane, R. D. MacArthur, and M. R. Fairfax. 2005. Discordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 Monitor (version 1.5) standard and ultrasensitive assays caused by freezing patient plasma in centrifuged Becton-Dickinson Vacutainer brand plasma preparation tubes. J. Clin. Microbiol. 43:4635-4639.
12. Sharkey, M. K. T., D. R. Kuritzkes, and M. Stevenson. 2005. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J. Virol. 79:5203-5210.
13. Squires, K., A. Lazzarin, J. M. Gatell, W. G. Powderly, V. Pokrovskiy, J.-F. Delfraissy, J. Jemsek, A. Rivero, W. Rozenbaum, S. Schrader, M. Sension, A. Vibhagool, A. Thiry, and M. Giordano. 2004. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36:1011-1019.
14. Stosor, V., F. J. Palella, Jr., B. Berzins, M. Till, A. Leake, J. S. Chmiel, and R. L. Murphy. 2005. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin. Infect. Dis. 41:1671-1674.